[1] M. d’Alessandro, P. Cameli, R.M. Refini, L. Bergantini, V. Alonzi, N. Lanzarone, D. Bennett, G.D. Rana, F. Montagnani, S. Scolletta, F. Franchi, B. Frediani, S. Valente, M.A. Mazzei, F. Bonella, E. Bargagli, Serum KL-6 concentrations as a novel biomarker of severe COVID-19, J Med Virol. 92 (2020) 2216–2220. https://doi.org/10.1002/jmv.26087.
[2] X. Li, X. Ma, Acute respiratory failure in COVID-19: is it “typical” ARDS?, Crit Care. 24 (2020) 198. https://doi.org/10.1186/s13054-020-02911-9.
[3] J.R. Greenland, M.D. Michelow, L. Wang, M.J. London, COVID-19 Infection: Implications for Perioperative and Critical Care Physicians, Anesthesiology. 132 (2020) 1346–1361. https://doi.org/10.1097/ALN.0000000000003303.
[4] From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), D. Sacks, B. Baxter, B.C.V. Campbell, J.S. Carpenter, C. Cognard, D. Dippel, M. Eesa, U. Fischer, K. Hausegger, J.A. Hirsch, M. Shazam Hussain, O. Jansen, M.V. Jayaraman, A.A. Khalessi, B.W. Kluck, S. Lavine, P.M. Meyers, S. Ramee, D.A. Rüfenacht, C.M. Schirmer, D. Vorwerk, Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke, Int J Stroke. 13 (2018) 612–632. https://doi.org/10.1177/1747493018778713.
[5] B. Hu, H. Guo, P. Zhou, Z.-L. Shi, Characteristics of SARS-CoV-2 and COVID-19, Nat Rev Microbiol. 19 (2021) 141–154. https://doi.org/10.1038/s41579-020-00459-7.
[6] COVID-19 cytokine storm: targeting the appropriate cytokine - The Lancet Rheumatology, (n.d.). https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00011-4/fulltext (accessed June 11, 2021).
[7] Frontiers | Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in” | Immunology, (n.d.). https://www.frontiersin.org/articles/10.3389/fimmu.2020.02132/full (accessed June 11, 2021).
[8] K. Dorgham, P. Quentric, M. Gökkaya, S. Marot, C. Parizot, D. Sauce, A. Guihot, C.-E. Luyt, M. Schmidt, J. Mayaux, A. Beurton, L. Le Guennec, S. Demeret, E. Ben Salah, A. Mathian, H. Yssel, B. Combadiere, C. Combadiere, C. Traidl-Hoffmann, S. Burrel, A.-G. Marcelin, Z. Amoura, G. Voiriot, A.U. Neumann, G. Gorochov, Distinct cytokine profiles associated with COVID-19 severity and mortality, J Allergy Clin Immunol. 147 (2021) 2098–2107. https://doi.org/10.1016/j.jaci.2021.03.047.
[9] S. Lopez-Castaneda, N. García-Larragoiti, A. Cano-Mendez, K. Blancas-Ayala, G. Damian-Vázquez, A.I. Perez-Medina, L.D. Chora-Hernández, C. Arean-Martínez, M.E. Viveros-Sandoval, Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection, Clin Appl Thromb Hemost. 27 (2021) 1076029621999099. https://doi.org/10.1177/1076029621999099.
[10] Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq, (n.d.). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250330 (accessed June 11, 2021).
[11] S.-H. Kim, S.-Y. Han, T. Azam, D.-Y. Yoon, C.A. Dinarello, Interleukin-32: a cytokine and inducer of TNFalpha, Immunity. 22 (2005) 131–142. https://doi.org/10.1016/j.immuni.2004.12.003.
[12] K.S. Cho, S.H. Park, S.H. Joo, S.-H. Kim, C.Y. Shin, The effects of IL-32 on the inflammatory activation of cultured rat primary astrocytes, Biochem Biophys Res Commun. 402 (2010) 48–53. https://doi.org/10.1016/j.bbrc.2010.09.099.
[13] Interleukin 32: a novel player in the control of infectious diseases - Ribeiro‐Dias - 2017 - Journal of Leukocyte Biology - Wiley Online Library, (n.d.). https://jlb.onlinelibrary.wiley.com/doi/full/10.1189/jlb.4RU0416-175RR (accessed June 11, 2021).
[14] M.B. Khawar, M.H. Abbasi, N. Sheikh, IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis, Mediators of Inflammation. 2016 (2016) 1–8. https://doi.org/10.1155/2016/8413768.
[15] Y. Chi, Y. Ge, B. Wu, W. Zhang, T. Wu, T. Wen, J. Liu, X. Guo, C. Huang, Y. Jiao, F. Zhu, B. Zhu, L. Cui, Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China, J Infect Dis. 222 (2020) 746–754. https://doi.org/10.1093/infdis/jiaa363.
[16] J.M. Chertoff, Negative oedipal transference of a male patient to his female analyst during the termination phase, J Am Psychoanal Assoc. 37 (1989) 687–713. https://doi.org/10.1177/000306518903700305.
[17] H. Imaeda, A. Andoh, T. Aomatsu, R. Osaki, S. Bamba, O. Inatomi, T. Shimizu, Y. Fujiyama, A new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29, Mol Med Rep. 4 (2011) 483–487. https://doi.org/10.3892/mmr.2011.442.
[18] B. Heinhuis, T.S. Plantinga, G. Semango, B. Küsters, M.G. Netea, C.A. Dinarello, J.W.A. Smit, R.T. Netea-Maier, L.A.B. Joosten, Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines, Carcinogenesis. 37 (2016) 197–205. https://doi.org/10.1093/carcin/bgv172.
[19] K. Ouhara, T. Kawai, M.J.B. Silva, T. Fujita, K. Hayashida, N.Y. Karimbux, M. Kajiya, H. Shiba, H. Kawaguchi, H. Kurihara, Expression levels of novel cytokine IL-32 in periodontitis and its role in the suppression of IL-8 production by human gingival fibroblasts stimulated with Porphyromonas gingivalis, Journal of Oral Microbiology. 4 (2012) 14832. https://doi.org/10.3402/jom.v4i0.14832.
[20] S.T. Rasool, H. Tang, J. Wu, W. Li, M.M. Mukhtar, J. Zhang, Y. Mu, H.X. Xing, J. Wu, Y. Zhu, Increased level of IL-32 during human immunodeficiency virus infection suppresses HIV replication, Immunol Lett. 117 (2008) 161–167. https://doi.org/10.1016/j.imlet.2008.01.007.
[21] B.M. Henry, I. Cheruiyot, J. Vikse, V. Mutua, V. Kipkorir, J. Benoit, M. Plebani, N. Bragazzi, G. Lippi, Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis, Acta Biomed. 91 (2020) e2020008. https://doi.org/10.23750/abm.v91i3.10217.
[22] E.E. Lee, K.-H. Song, W. Hwang, S.Y. Ham, H. Jeong, J.-H. Kim, H.S. Oh, Y.M. Kang, E.B. Lee, N.J. Kim, B.S. Chin, J.K. Park, Pattern of inflammatory immune response determines the clinical course and outcome of COVID-19: unbiased clustering analysis, Sci Rep. 11 (2021) 8080. https://doi.org/10.1038/s41598-021-87668-z.
[23] K. Singh, S. Mittal, S. Gollapudi, A. Butzmann, J. Kumar, R.S. Ohgami, A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity, Int J Lab Hematol. 43 (2021) 324–328. https://doi.org/10.1111/ijlh.13354.
[24] E. Grifoni, A. Valoriani, F. Cei, R. Lamanna, A.M.G. Gelli, B. Ciambotti, V. Vannucchi, F. Moroni, L. Pelagatti, R. Tarquini, G. Landini, S. Vanni, L. Masotti, Interleukin-6 as prognosticator in patients with COVID-19, J Infect. 81 (2020) 452–482. https://doi.org/10.1016/j.jinf.2020.06.008.
[25] T. Herold, V. Jurinovic, C. Arnreich, B.J. Lipworth, J.C. Hellmuth, M. von Bergwelt-Baildon, M. Klein, T. Weinberger, Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, J Allergy Clin Immunol. 146 (2020) 128-136.e4. https://doi.org/10.1016/j.jaci.2020.05.008.
[26] S.S. Iyer, G. Cheng, Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease, Crit Rev Immunol. 32 (2012) 23–63. https://doi.org/10.1615/critrevimmunol.v32.i1.30.
[27] L. Bergantini, E. Bargagli, M. d’Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta, Prognostic bioindicators in severe COVID-19 patients, Cytokine. 141 (2021) 155455. https://doi.org/10.1016/j.cyto.2021.155455.